Price T Rowe Associates Inc. MD Has $62.31 Million Stake in Edwards Lifesciences Corporation $EW

Key Points

• Price T Rowe Associates Inc. MD significantly reduced its stake in Edwards Lifesciences by 73.9%, selling over 2.4 million shares, leaving it with approximately 859,694 shares valued at $62.3 million.
• Institutional investors and hedge funds collectively hold 79.46% of Edwards Lifesciences, showing significant institutional interest in the company.
• Several analysts have recently increased their price targets for Edwards Lifesciences, with an average target of $85.90 and a consensus rating of "Moderate Buy".

Price T Rowe Associates Inc. MD lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 73.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 859,694 shares of the medical research company's stock after selling 2,438,028 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.15% of Edwards Lifesciences worth $62,312,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Vega Investment Solutions acquired a new position in Edwards Lifesciences during the 4th quarter worth $27,000. Quantbot Technologies LP acquired a new position in Edwards Lifesciences during the 1st quarter worth $26,000. SouthState Corp acquired a new position in Edwards Lifesciences during the 1st quarter worth $27,000. Rossby Financial LCC acquired a new position in Edwards Lifesciences during the 1st quarter worth $29,000. Finally, Costello Asset Management INC acquired a new position in Edwards Lifesciences during the 1st quarter worth $29,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on EW shares. Mizuho boosted their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Argus upgraded Edwards Lifesciences to a "strong-buy" rating in a report on Thursday, July 10th. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Canaccord Genuity Group upped their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a report on Friday, July 25th. Finally, Piper Sandler upped their price objective on Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of "Moderate Buy" and a consensus target price of $85.90.

Insider Activity at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider directly owned 206,900 shares of the company's stock, valued at approximately $15,565,087. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,584 shares of company stock valued at $1,897,762. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Trading Up 0.3%

Shares of NYSE EW traded up $0.25 during mid-day trading on Friday, hitting $81.48. 2,743,784 shares of the company traded hands, compared to its average volume of 3,822,878. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00. The stock has a market capitalization of $47.84 billion, a price-to-earnings ratio of 11.72, a PEG ratio of 3.92 and a beta of 1.08. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The business has a 50 day moving average of $78.31 and a two-hundred day moving average of $75.02.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the business posted $0.70 earnings per share. Edwards Lifesciences's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.